Bionano Genomics, Inc. is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).
äŒæ¥ã³ãŒãBNGO
äŒç€ŸåBionano Genomics Inc
äžå Žæ¥Aug 01, 2018
æé«çµå¶è²¬ä»»è
ãCEOãHolmlin (R. Erik)
åŸæ¥å¡æ°98
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Aug 01
æ¬ç€Ÿæåšå°9540 Towne Centre Drive
éœåžSAN DIEGO
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·92121
é»è©±çªå·18588887600
ãŠã§ããµã€ãhttps://bionano.com/
äŒæ¥ã³ãŒãBNGO
äžå Žæ¥Aug 01, 2018
æé«çµå¶è²¬ä»»è
ãCEOãHolmlin (R. Erik)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã